Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:56:30.589Z.
Calculation as of: 2026-10-06T18:56:30.589Z.
Quote observation: 2026-10-06T18:55:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4140271b5ba2e17517ffa776ba39ee0784cb590c71b20d0313403f3757235181
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.18B | N/A | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Tyra Biosciences, Inc. (TYRA)vs › | $1.20B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.22B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.15B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.23B | N/A | N/A | N/A | N/A |
| Omada Health (OMDA)vs › | $1.22B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.14B | N/A | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 0.11 | 0.23 | 0.28 | 0.35 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
